Nicola Mason is a Professor in the Department of Clinical Sciences and Advanced Medicine and holds the Paul A. James and Charles A. Gilmore Endowed Chair Professorship at the University of Pennsylvania’s School of Veterinary Medicine. She received her veterinary degree from the Royal Veterinary College, London and her Immunology PhD from the University of Pennsylvania. She performed her post -doctoral fellowship at the Abramson Cancer Center at the School of Medicine at UPenn. 

 Dr. Mason’s translational research group focuses on developing safe and effective immunotherapies for dogs with cancer, autoimmunity and infectious disease. Through comparative medicine her work aims to accelerate the clinical implementation of effective immunotherapies into the human and canine clinics, improving the lives of both species. Dr. Mason leads the first canine cancer immunotherapy consortium, supported by the National Institutes of Health Biden Cancer Moonshot initiative and her research using adoptive cell therapies is funded through multiple federal grants. Her pioneering work with a live, recombinant Listeria vaccine in dogs with osteosarcoma earned her the One Health Award for Excellence in promoting One Health Initiatives. Her research interests include adoptive immunotherapy using CAR-T cells in cancers including B cell malignancies and OSA and in autoimmunity and the development of antibody-based therapeutics for cancer, allergy and inflammation.